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Background: RRx-001 is a novel NO and hypoxia mediated antic-
ancer agent with epigenetic activity. In the ﬁrst-in-human, Phase I
trial, 5/5 patients who progressed on RRx-001 treatment were
resensitized to previously refractory therapy, hinting at a general-
ized resensitization effect.
Aims: A randomized open-label multi-part, multi-center phase II
trial of RRx-001 versus regorafenib (ROCKET) has commenced to
explore the resensitization and/or ‘episensitization’ potential in
irinotecan refractory tumors and its impact on overall survival.
Methods: Patients with irinotecan-refractory metastatic colorectal
cancer with an ECOG PS 0–1 who progressed on oxaliplatin-, and
irinotecan-based regimens with or without bevacizumab, cetux-
imab or panitumumab are randomized 2:1 to receive RRx-001
16.5 mg/m2 IV 1x/week or regorafenib 160 mg orally 21 of 28 days
until progression or unacceptable toxicity followed by treatment
with refractory irinotecan-based therapies.
Results: To date, 26 patients have been randomized with 18
patients evaluable for resensitization. Post RRx-001 patients
demonstrated marked decreases in CEA in 12/13 patients as
compared to 5 patients receiving regorafenib who were too
systemically unwell to proceed to subsequent treatment. Progres-
sion free survival (ongoing) for RRx-001+irinotecan is 4.9 months
compared 1.8 months on Regorafenib+irinotecan.
Conclusion: Early results in the ROCKET study suggest that RRx-
001-mediated resensitization to previously refractory therapies
may have a generalized effect, independent of KRAS or p53 status.
These early results are intriguing, suggesting improved QOL and
overall survival over currently approved therapy in the chemother-
apy refractory colorectal cancer.
http://dx.doi.org/10.1016/j.redox.2015.09.035
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Vascular endothelial growth factor (VEGF) and its receptor
(VEGFR) are overexpressed in the majority of renal cell carcinomas
(RCC). This characteristic has supported the rationale of targeting
VEGF-driven tumour vascularization, especially in clear cell RCC.
VEGF-inhibiting strategies include the use of tyrosine kinase
inhibitors (sunitinib, axitinib, pazopanib, and sorafenib) and neu-
tralizing antibodies such as bevacizumab.
Hypertension (HT) is one of the most common adverse effects
of angiogenesis inhibitors. Hypertension observed in clinical trials
appears to correlate with the potency of VEGF kinase inhibitor
against VEGFR-2: agents with higher potency are associated with a
higher incidence of hypertension. Although the exact mechanism
by TKIs induce hypertension has not yet been completely clariﬁed,
two key hypotheses have been postulated. First, some studies have
pointed to a VEGF inhibitors-induced decrease in nitric oxide
synthase (NOS) and nitric oxide (NO) production, that can result
in vasoconstriction and increased blood pressure. VEGF, mediated
by PI3K/Akt and MAPK pathway, upregulates the endothelial nitric
oxide synthase enzyme leading to up-regulation of NO production.
So inhibition of signaling through the VEGF pathway would lead to
a decrease in NO production, resulting in an increase in vascular
resistance and blood pressure. Secondly a decrease in the number
of microvascular endothelial cells and subsequent depletion of
normal microvessel density (rarefaction) occurs upon VEGF signal-
ing inhibition.
http://dx.doi.org/10.1016/j.redox.2015.09.036
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Photodynamic therapy (PDT) is a clinically approved treatment
that causes a selective cytotoxic effect in cancer cells. In addition
to the production of singlet oxygen and reactive oxygen species,
PDT can induce the release of nitric oxide (NO) by up-regulating
nitric oxide synthases (NOS). Since non-optimal PDT often causes
tumor recurrence, understanding of the molecular pathways
involved in the photoprocess is a challenging task for scientists.
The present study has examined the response of the PC3 human
metastatic prostate cancer cell line, following repeated low-dose
pheophorbide a treatments, mimicking non-optimal PDT treat-
ment. The analysis was focused on the NF-kB/YY1/RKIP circuitry as
it is (i) dysregulated in cancer cells (ii) modulated by NO and (iii)
correlated with the epithelial to mesenchymal transition (EMT).
We hypothesized that a repeated treatment of non-optimal PDT
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